Should adenosquamous esophageal cancer be treated like adenocarcinoma or squamous cell carcinoma?
- 27 May 2020
- journal article
- research article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 122 (3) , 412-421
Abstract
Background Esophageal adenocarcinoma (AC) and squamous cell carcinoma (SCC) have distinct outcomes, treatment strategies, and response profiles to therapy. Adenosquamous carcinoma (ASC) is thought to behave more aggressively than each of its counterparts. The aim of this study is to determine if ASC is best managed as AC or SCC. Methods National Cancer Database (2004‐2015) was queried for patients with nonmetastatic esophageal ASC. The analysis was stratified by clinical node‐negative (cN0) or clinical node‐positive (cN1‐3). Treatment was categorized into chemoradiation alone, surgery alone, or preoperative chemoradiation followed by surgery. The primary outcome was 5‐year overall survival (OS). Results Among 352 patients, 43% were cN0 (n = 151), 57% were cN1‐3 (n = 201) and 55% had chemoradiation alone (n = 194), 15% surgery alone (n = 53), and 30% preoperative chemoradiation (n = 105). Among patients who had preoperative chemoradiation, 20% had pathologic complete response (n = 17). For either cN0 or cN1‐3, Charlson‐Deyo Comorbidity Index did not differ among the treatment groups (all p > 0.05). On Kaplan‐Meier analysis for cN0, treatment with surgery alone had comparable OS to preoperative chemoradiation (47% vs 34%; P = .5) and each had improved OS compared to chemoradiation alone (30%; P = .02; P = .06). On univariate analysis for cN0, clinical T category was not associated with OS. For cN1‐3, however, preoperative chemoradiation was associated with improved OS when compared to chemoradiation alone or surgery alone (27% vs 19% vs 0%; P < .001). This persisted when accounting for age and clinical T category (hazard ratio: 0.45; P < .001). Conclusion Esophageal ASC behaves more like AC in response to chemoradiation and survival based on treatment modality. A complete response to chemoradiation is only 20% unlike what has been shown for SCC, where chemoradiation is an acceptable definitive therapy. Esophageal ASC should be managed more like AC.Keywords
Funding Information
- The Abraham J. & Phyllis Katz Foundation
This publication has 27 references indexed in Scilit:
- Trends in esophageal adenocarcinoma incidence and mortalityCancer, 2012
- Preoperative Chemoradiotherapy for Esophageal or Junctional CancerNew England Journal of Medicine, 2012
- A Phase II Trial of Chemoradiotherapy for Stage I Esophageal Squamous Cell Carcinoma: Japan Clinical Oncology Group Study (JCOG9708)Japanese Journal of Clinical Oncology, 2009
- Phase III Comparison of Preoperative Chemotherapy Compared With Chemoradiotherapy in Patients With Locally Advanced Adenocarcinoma of the Esophagogastric JunctionJournal of Clinical Oncology, 2009
- Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosisAnnals of Oncology, 2008
- Chemoradiation Followed by Surgery Compared With Chemoradiation Alone in Squamous Cancer of the Esophagus: FFCD 9102Journal of Clinical Oncology, 2007
- Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal CancerNew England Journal of Medicine, 2006
- Chemoradiation With and Without Surgery in Patients With Locally Advanced Squamous Cell Carcinoma of the EsophagusJournal of Clinical Oncology, 2005
- Adenosquamous Carcinoma of the EsophagusOncology, 2004
- Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trialThe Lancet, 2002